Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lorus Therapeutics has received a new patent from the US Patent and Trademark Office for its clinical-stage anticancer drug LOR-2040.
Subscribe to our email newsletter
The patent protects methods of treating leukemia with LOR-2040, both alone and in combination with chemotherapy drugs. The patent also covers methods of treating specific solid cancers with LOR-2040, including colon, lung, breast, and bladder cancers. LOR-2040 composition as well as its design and use as a unique anticancer drug is currently protected in the US under a separate patent issued in 1999.
The company announced that in a recently completed proof-of-concept clinical trial, patients with relapsed or refractory acute myeloid leukemia (AML) showed a 35% complete response rate, accumulation of LOR-2040 in tumor cells, and down regulation of its biochemical target following treatment with LOR-2040 in combination with HiDAC.
Aiping Young, Lorus’s president and CEO, said: “This newly issued US patent adds additional strength to our global IP position for this drug, and supports the potential development in other cancers in a major market.”